OBJECTIVES/HYPOTHESIS: To report on single-center data of an FDA-approved clinical trial on the objective benefits of cochlear implantation and subsequent ipsilateral Electric-Acoustic Stimulation (EAS). STUDY DESIGN: Single-center data from a prospective, multicenter clinical trial. METHODS: Eighteen subjects completed the 12-month EAS evaluation and were included in this evaluation. Each patient underwent cochlear implantation using a standardized hearing preservation approach. Both hearing preservation and speech perception abilities were evaluated at various intervals. Speech testing included performance measures obtained in quiet (CNC words) and noise (adaptive CUNY protocol) in three listening conditions: hearing aid (HA) alone, cochlear implant (CI) only, and combined ipsilateral EAS. RESULTS: Various levels of hearing preservation were achieved with cochleostomy and round-window surgical approaches in 17 of the 18 subjects. Mean CNC word scores at the 12-month interval were 14.9 ± 12.1, 45.3 ± 15.4, and 70.7 ± 11.7% correct in the HA only, CI only, and EAS conditions, respectively. Average CUNY scores at 0 dB SNR were 14.6 ± 17.2, 47.1 ± 22.1, and 72.2 ± 21.5 for the three test conditions obtained after 12 months. CONCLUSIONS: Data obtained during this clinical trial correlate well with previous reports. Hearing preservation appears successful in a high number of subjects, and combined EAS offers excellent speech perception abilities in quiet and in noise. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: To report on single-center data of an FDA-approved clinical trial on the objective benefits of cochlear implantation and subsequent ipsilateral Electric-Acoustic Stimulation (EAS). STUDY DESIGN: Single-center data from a prospective, multicenter clinical trial. METHODS: Eighteen subjects completed the 12-month EAS evaluation and were included in this evaluation. Each patient underwent cochlear implantation using a standardized hearing preservation approach. Both hearing preservation and speech perception abilities were evaluated at various intervals. Speech testing included performance measures obtained in quiet (CNC words) and noise (adaptive CUNY protocol) in three listening conditions: hearing aid (HA) alone, cochlear implant (CI) only, and combined ipsilateral EAS. RESULTS: Various levels of hearing preservation were achieved with cochleostomy and round-window surgical approaches in 17 of the 18 subjects. Mean CNC word scores at the 12-month interval were 14.9 ± 12.1, 45.3 ± 15.4, and 70.7 ± 11.7% correct in the HA only, CI only, and EAS conditions, respectively. Average CUNY scores at 0 dB SNR were 14.6 ± 17.2, 47.1 ± 22.1, and 72.2 ± 21.5 for the three test conditions obtained after 12 months. CONCLUSIONS: Data obtained during this clinical trial correlate well with previous reports. Hearing preservation appears successful in a high number of subjects, and combined EAS offers excellent speech perception abilities in quiet and in noise. LEVEL OF EVIDENCE: 4.
Authors: Margaret T Dillon; Brendan P O'Connell; Michael W Canfarotta; Emily Buss; Joseph Hopfinger Journal: Am J Audiol Date: 2022-04-08 Impact factor: 1.636
Authors: Margaret T Dillon; Emily Buss; English R King; Ellen J Deres; Sarah N Obarowski; Meredith L Anderson; Marcia C Adunka Journal: Cochlear Implants Int Date: 2016-10-18
Authors: Alicia M Quesnel; Hideko Heidi Nakajima; John J Rosowski; Marlan R Hansen; Bruce J Gantz; Joseph B Nadol Journal: Hear Res Date: 2015-09-01 Impact factor: 3.208
Authors: Tatyana Elizabeth Fontenot; Christopher Kenneth Giardina; Margaret Dillon; Meredith A Rooth; Holly F Teagle; Lisa R Park; Kevin David Brown; Oliver F Adunka; Craig A Buchman; Harold C Pillsbury; Douglas C Fitzpatrick Journal: Ear Hear Date: 2019 May/Jun Impact factor: 3.570
Authors: Kati Härkönen; Ilkka Kivekäs; Voitto Kotti; Ville Sivonen; Juha-Pekka Vasama Journal: Eur Arch Otorhinolaryngol Date: 2017-07-31 Impact factor: 2.503
Authors: Elizabeth L Perkins; Nauman F Manzoor; David S Haynes; Matthew O'Malley; René Gifford; Alejandro Rivas Journal: Otol Neurotol Date: 2021-07-01 Impact factor: 2.311
Authors: Elizabeth Perkins; Jaclyn Lee; Nauman Manzoor; Matthew O'Malley; Marc Bennett; Robert Labadie; Alejandro Rivas; David Haynes; René Gifford Journal: Otol Neurotol Date: 2021-07-01 Impact factor: 2.311